You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):"多西他賽注射液"獲通過一致性評價
格隆匯 02-25 16:44

格隆匯 2 月 25日丨中國生物製藥(01177.HK)宣佈,集團的抗腫瘤藥"多西他賽注射液"(商品名:泰正欣)已獲中華人民共和國國家藥品監督管理局頒發藥品補充申請批准通知書,獲通過仿製藥質量和療效一致性評價。該產品適用於乳腺癌、非小細胞肺癌、前列腺癌、胃癌的治療。

多西他賽又名多西紫杉醇,是半合成的紫杉醇衍生物,屬於微管解聚抑制劑。多西他賽注射液是國內治療腫瘤的常用藥物之一,具有較高的醫生認知度,並已入選了2009版的《國家基本醫療保險和工傷保險藥品目錄》。多西他賽注射液的市場成熟且規模可觀。集團研製的多西他賽注射液的規格為1ml:20mg(非濃縮液),具有無需二次稀釋、臨牀使用方便的優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account